Analysis and comparison of statin prescription patterns and outcomes according to clinical department

Kim, H.-S.; Kim, H.; Lee, H.; Park, B.; Park, Seonyoung; Lee, S.-H.; Cho, J. H.; Song, Ho-Jun; Kim, J. H.; Yoon, Kun‐Ho; Choi, In Young

doi:10.1111/jcpt.12350

Cited by 16 publications

(18 citation statements)

References 33 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This result seems acceptable because Asians achieve similar benefits as Westerners at lower statin doses . Furthermore, moderate‐intensity statins have demonstrated a low‐density lipoprotein cholesterol (LDL‐C)‐lowering effect of more than a 50% reduction in Korean patients with baseline LDL‐C levels above 190 mg/dl . According to the 2013 ACC/AHA guideline definitions, these patients received high‐intensity statins because high‐intensity statin therapy was defined as statins lowering LDL‐C levels by ~50% or more.…”

Section: Discussionmentioning

confidence: 99%

“…35 Furthermore, moderate-intensity statins have demonstrated a low-density lipoprotein cholesterol (LDL-C)-lowering effect of more than a 50% reduction in Korean patients with baseline LDL-C levels above 190 mg/dl. [36][37][38] According to the 2013 ACC/ AHA guideline definitions, 26 these patients received high-intensity statins because highintensity statin therapy was defined as statins lowering LDL-C levels by~50% or more. Due to these intensity disparities, recommendations from the ACC/AHA guidelines should be carefully interpreted when applying them to Asian patients.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Effectiveness of Combination Therapy with Statins and Angiotensin‐Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea

Lee

2018

Pharmacotherapy

View full text Add to dashboard Cite

A MACCE was less likely to occur in patients who received a statin-ARB than in those who received a statin-ACEI. Similar trends were seen in cardiovascular mortality and the occurrence of recurrent MI but not stroke. The availability of statin-ARB fixed-dose combinations may have contributed to the improved outcomes in the statin-ARB cohort by reducing pill burden and improving medication adherence. Further research is warranted to validate our findings and to address whether a particular statin-ARB combination is more effective than other combinations.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparative Effectiveness of Combination Therapy with Statins and Angiotensin‐Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea

Lee

2018

Pharmacotherapy

View full text Add to dashboard Cite

show abstract

“…Prescription rates of each department have been analyzed along with prescription patterns [26]. In a previous study, cardiologists were determined to be the most frequent prescribers of statins [26].…”

Section: Discussionmentioning

confidence: 99%

Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research

Kim

Jeong

et al. 2017

Endocrinol Metab

View full text Add to dashboard Cite

BackgroundThe increasing use of electronic medical record (EMR) systems for documenting clinical medical data has led to EMR data being increasingly accessed for clinical trials. In this study, a database of patients who were prescribed statins for the first time was developed using EMR data. A clinical data mart (CDM) was developed for cohort study researchers.MethodsSeoul St. Mary's Hospital implemented a clinical data warehouse (CDW) of data for ~2.8 million patients, 47 million prescription events, and laboratory results for 150 million cases. We developed a research database from a subset of the data on the basis of a study protocol. Data for patients who were prescribed a statin for the first time (between the period from January 1, 2009 to December 31, 2015), including personal data, laboratory data, diagnoses, and medications, were extracted.ResultsWe extracted initial clinical data of statin from a CDW that was established to support clinical studies; the data was refined through a data quality management process. Data for 21,368 patients who were prescribed statins for the first time were extracted. We extracted data every 3 months for a period of 1 year. A total of 17 different statins were extracted. It was found that statins were first prescribed by the endocrinology department in most cases (69%, 14,865/21,368).ConclusionStudy researchers can use our CDM for statins. Our EMR data for statins is useful for investigating the effectiveness of treatments and exploring new information on statins. Using EMR is advantageous for compiling an adequate study cohort in a short period.

show abstract

“…In 2013, according to the American College of Cardiology and American Heart Association (ACC/AHA) guidelines, statins were classified into high‐, moderate‐ and low‐intensity groups according to the LDL‐C reduction rate. In Korea, a previous study classified statins into high‐, moderate‐to‐high‐, moderate‐to‐low‐ and low‐intensity groups according to the LDL‐C reduction rate, and we used this classification system.…”

Section: Methodsmentioning

confidence: 99%

“…Many statins and different dosages are being prescribed around the world, and the different types and dosages have different LDL‐C reduction rates, target achievement rates, side effects and costs . Physicians should consider not only the clinical aspects, such as the LDL‐C reduction rate, the target achievement rate and side effects, but also the cost of each statin.…”

Section: What Is Known and Objectivementioning

confidence: 99%

Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea

et al. 2017

Self Cite

View full text Add to dashboard Cite

Summary What is known and objective There are a few Korean studies on the economics of statins based on reduction in low‐density lipoprotein cholesterol (LDL‐C) data from other countries. This study aimed to analyse and compare the cost‐effectiveness of statins according to the baseline LDL‐C level in Korea. Methods Between January 2009 and December 2015, the data of patients who were prescribed statins for the first time were extracted from electronic medical records. We performed a cost‐effectiveness analysis (CEA) based on the LDL‐C reduction rate (CEA‐RR) and target achievement rate. Results and discussion Among high‐intensity statins, the CEA‐RR value of rosuvastatin (20 mg) was significantly lower than that of atorvastatin (40 mg) at all baseline LDL‐C levels, except levels of 160–189 mg/dL. Additionally, at baseline LDL‐C levels of 130–159 mg/dL, the CEA‐RR value of rosuvastatin (20 mg) was three times lower than that of atorvastatin (40 mg) (9·1 ± 2·5 $/% vs. 31·7 ± 15·0 $/%, P < 0·001). Among moderate‐to‐low‐intensity statins, rosuvastatin (5 mg) showed the lowest CEA‐RR value (4·0 ± 0·6 $/%), and the value significantly increased for pitavastatin (2 mg) (8·0 ± 0·6 $/%), atorvastatin (10 mg) (9·5 ± 0·5 $/%), simvastatin (10·8 ± 1·1 $/%) and pravastatin (40 mg) (11·5 ± 0·9 $/%) in order (P < 0·0001). On changing from atorvastatin (10 mg) to atorvastatin (20 mg), the additional yearly cost was 16·0 and additional CEA‐RR value was 2·74 $/%. On the other hand, on changing from atorvastatin (10 mg) to rosuvastatin (10 mg), the additional yearly cost was −16·3 and additional CEA‐RR value was −1·8 $/%. What is new and conclusion We successfully compared the cost‐effectiveness of statins according to the baseline LDL‐C level in Korea. It is expected that our findings will help clinical decision‐making with regard to statin prescription, and this will help reduce national medical expenditure.

show abstract

Analysis and comparison of statin prescription patterns and outcomes according to clinical department

Cited by 16 publications

References 33 publications

Comparative Effectiveness of Combination Therapy with Statins and Angiotensin‐Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea

Comparative Effectiveness of Combination Therapy with Statins and Angiotensin‐Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population‐Based Cohort Study in Korea

Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research

Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea

Contact Info

Product

Resources

About